{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:35:30Z","timestamp":1777955730962,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04870-z","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:17:02Z","timestamp":1774466222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionated radiotherapy for prostate cancer: a bibliometric analysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Lingling","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupeng","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baolin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"4","key":"4870_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003.","journal-title":"Eur Urol"},{"issue":"2","key":"4870_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042.","journal-title":"Eur Urol"},{"key":"4870_CR3","doi-asserted-by":"publisher","first-page":"1349888","DOI":"10.3389\/fonc.2024.1349888","volume":"14","author":"Y Di","year":"2024","unstructured":"Di Y, Song J, Song Z, Wang Y, Meng L. Prognostic nomogram to predict cancer-specific survival with small-cell carcinoma of the prostate: a multi-institutional study. Front Oncol. 2024;14:1349888. https:\/\/doi.org\/10.3389\/fonc.2024.1349888.","journal-title":"Front Oncol"},{"key":"4870_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.07.137","author":"Y Di","year":"2024","unstructured":"Di Y, Song J, Wang Y, Meng L. Immunotherapy for small cell carcinoma of the prostate: a new treatment frontier. Asian J Surg. 2024. https:\/\/doi.org\/10.1016\/j.asjsur.2024.07.137.","journal-title":"Asian J Surg"},{"issue":"10323","key":"4870_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"key":"4870_CR6","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0167-8140(04)80012-4","volume":"73","author":"H Tsujii","year":"2004","unstructured":"Tsujii H, Mizoe J, Kamada T, et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004;73:S41\u20139. https:\/\/doi.org\/10.1016\/S0167-8140(04)80012-4.","journal-title":"Radiother Oncol"},{"key":"4870_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00140","volume":"6","author":"DK Ebner","year":"2016","unstructured":"Ebner DK, Kamada T. The emerging role of carbon-ion radiotherapy. Front Oncol. 2016;6:140. https:\/\/doi.org\/10.3389\/fonc.2016.00140.","journal-title":"Front Oncol"},{"issue":"17","key":"4870_CR8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884. https:\/\/doi.org\/10.1200\/JCO.2016.71.7397.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4870_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018;8(6):354\u201360. https:\/\/doi.org\/10.1016\/j.prro.2018.08.002.","journal-title":"Pract Radiat Oncol"},{"issue":"8","key":"4870_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","volume":"51","author":"A Dasu","year":"2012","unstructured":"Dasu A, Toma-Dasu I. Prostate alpha\/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51(8):963\u201374. https:\/\/doi.org\/10.3109\/0284186X.2012.719635.","journal-title":"Acta Oncol"},{"issue":"1","key":"4870_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","volume":"85","author":"IR Vogelius","year":"2013","unstructured":"Vogelius IR, Bentzen SM. Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85(1):89\u201394. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4870_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clon.2007.02.007","volume":"19","author":"A Dasu","year":"2007","unstructured":"Dasu A. Is the \u03b1\/\u03b2 value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol. 2007;19(5):289\u2013301. https:\/\/doi.org\/10.1016\/j.clon.2007.02.007.","journal-title":"Clin Oncol"},{"issue":"1","key":"4870_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijrobp.2009.10.008","volume":"79","author":"C Proust-Lima","year":"2011","unstructured":"Proust-Lima C, Taylor JMG, Secher S, et al. Confirmation of a low \u03b1\/\u03b2 ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for psa dynamics. Int J Radiat Oncol Biol Phys. 2011;79(1):195\u2013201. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"4870_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrclinonc.2012.194","volume":"9","author":"DA Jaffray","year":"2012","unstructured":"Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol. 2012;9(12):688\u201399. https:\/\/doi.org\/10.1038\/nrclinonc.2012.194.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4870_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/153303460600500503","volume":"5","author":"JS Welsh","year":"2006","unstructured":"Welsh JS, Lock M, Harari PM, et al. Clinical implementation of adaptive helical tomotherapy:: a unique approach to image-guided intensity modulated radiotherapy. Technol Cancer Res Treat. 2006;5(5):465\u201379. https:\/\/doi.org\/10.1177\/153303460600500503.","journal-title":"Technol Cancer Res Treat"},{"key":"4870_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.addr.2016.09.002","volume":"109","author":"K Tanderup","year":"2017","unstructured":"Tanderup K, Menard C, Polgar C, Lindegaard JC, Kirisits C, Poetter R. Advancements in brachytherapy. Adv Drug Deliv Rev. 2017;109:15\u201325. https:\/\/doi.org\/10.1016\/j.addr.2016.09.002.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"4870_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00066-011-2236-4","volume":"187","author":"J Boda-Heggemann","year":"2011","unstructured":"Boda-Heggemann J, Lohr F, Wenz F, Flentje M, Guckenberger M. kV cone-beam CT-based IGRT a clinical review. Strahlenther Onkol. 2011;187(5):284\u201391. https:\/\/doi.org\/10.1007\/s00066-011-2236-4.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"4870_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.semradonc.2007.07.003","volume":"17","author":"M van Herk","year":"2007","unstructured":"van Herk M. Different styles of image-guided radiotherapy. Semin Radiat Oncol. 2007;17(4):258\u201367. https:\/\/doi.org\/10.1016\/j.semradonc.2007.07.003.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"4870_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","volume":"7","author":"SS Lo","year":"2010","unstructured":"Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44\u201354. https:\/\/doi.org\/10.1038\/nrclinonc.2009.188.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10196","key":"4870_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet"},{"issue":"4","key":"4870_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ijrobp.2008.05.059","volume":"73","author":"CR King","year":"2009","unstructured":"King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase ii clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.05.059.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4870_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","volume":"151","author":"D Keizer","year":"2020","unstructured":"Keizer D, Kerkmeijer GW, Willigenburg T, et al. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-linac. Radiother Oncol. 2020;151:88\u201394. https:\/\/doi.org\/10.1016\/j.radonc.2020.06.044.","journal-title":"Radiother Oncol"},{"issue":"13","key":"4870_CR23","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.29983","volume":"122","author":"GA Viani","year":"2016","unstructured":"Viani GA, Viana BS, Chicareli Martin JE, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer. 2016;122(13):2004\u201311. https:\/\/doi.org\/10.1002\/cncr.29983.","journal-title":"Cancer"},{"issue":"3","key":"4870_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.radonc.2018.07.027","volume":"129","author":"L Rossi","year":"2018","unstructured":"Rossi L, Bijman R, Schillemans W, et al. Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy. Radiother Oncol. 2018;129(3):548\u201353. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.027.","journal-title":"Radiother Oncol"},{"issue":"3","key":"4870_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ijrobp.2009.12.003","volume":"79","author":"S Lalondrelle","year":"2011","unstructured":"Lalondrelle S, Huddart R, Warren-Oseni K, et al. Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. Int J Radiat Oncol Biol Phys. 2011;79(3):705\u201312. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4870_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ijrobp.2012.01.004","volume":"84","author":"M Mizuta","year":"2012","unstructured":"Mizuta M, Takao S, Date H, et al. A mathematical study to select fractionation regimen based on physical dose distribution and the linear-quadratic model. Int J Radiat Oncol Biol Phys. 2012;84(3):829\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.01.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4870_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-117","volume":"28","author":"S Marzi","year":"2009","unstructured":"Marzi S, Saracino B, Petrongari MG, et al. Modeling of \u03b1\/\u03b2 for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res. 2009;28:117. https:\/\/doi.org\/10.1186\/1756-9966-28-117.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"4870_CR28","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ijrobp.2010.12.040","volume":"82","author":"F Leborgne","year":"2012","unstructured":"Leborgne F, Fowler J, Leborgne JH, Mezzera J. Later outcomes and alpha\/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(3):1200\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.12.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"4870_CR29","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1038\/bjc.2014.158","volume":"110","author":"MI Koukourakis","year":"2014","unstructured":"Koukourakis MI, Giatromanolaki A, Panteliadou M, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014;110(9):2217\u201323. https:\/\/doi.org\/10.1038\/bjc.2014.158.","journal-title":"Br J Cancer"},{"issue":"1","key":"4870_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12672-025-02181-3","volume":"16","author":"P Che","year":"2025","unstructured":"Che P, Zuo C, Tian J. Global trends in esophageal cancer and metabolic syndrome research: bibliometric analysis and visualization from 1995 to 2024. Discov Oncol. 2025;16(1):398.","journal-title":"Discov Oncol"},{"key":"4870_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003384","author":"K Jin","year":"2025","unstructured":"Jin K, Meng L, Yang J, Zhao C, Chen Y. Bibliometric and visualized analysis of the therapeutic application of suprachoroidal space from 2000 to 2024. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000003384.","journal-title":"Int J Surg"},{"issue":"1","key":"4870_CR32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1097\/JS9.0000000000002095","volume":"111","author":"J Tian","year":"2025","unstructured":"Tian J, Dong Y, Wang L, Wu Y, Zhao Z, Che G. Mapping the evolution of 3D printing in cardio-thoracic diseases: a global bibliometric analysis. Int J Surg. 2025;111(1):1629\u201335.","journal-title":"Int J Surg"},{"key":"4870_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ctro.2020.03.009","volume":"22","author":"R Simcock","year":"2020","unstructured":"Simcock R, Thomas TV, Estes C, et al. COVID-19: global radiation oncology\u2019s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020;22:55\u201368. https:\/\/doi.org\/10.1016\/j.ctro.2020.03.009.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"4870_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(20)30743-9","volume":"22","author":"K Spencer","year":"2021","unstructured":"Spencer K, Jones CM, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021;22(3):309\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(20)30743-9.","journal-title":"Lancet Oncol"},{"key":"4870_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2025.101021","volume":"54","author":"AL Zang","year":"2025","unstructured":"Zang AL, Maier T, Freitag-Wolf S, et al. PSMA response evaluation in follow-up PSMA-PET\/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer. Clin Transl Radiat Oncol. 2025;54:101021. https:\/\/doi.org\/10.1016\/j.ctro.2025.101021.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"4870_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/jrsm.1729","volume":"15","author":"M Gusenbauer","year":"2024","unstructured":"Gusenbauer M. Beyond Google Scholar, Scopus, and Web of Science: an evaluation of the backward and forward citation coverage of 59 databases\u2019 citation indices. Res Synth Methods. 2024;15(5):802\u201317.","journal-title":"Res Synth Methods"},{"issue":"2","key":"4870_CR37","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1097\/JS9.0000000000000868","volume":"110","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yi K, Xu JG, et al. Application of three-dimensional printing in cardiovascular diseases: a bibliometric analysis. Int J Surg. 2024;110(2):1068\u201378. https:\/\/doi.org\/10.1097\/JS9.0000000000000868.","journal-title":"Int J Surg"},{"issue":"2","key":"4870_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u201338. https:\/\/doi.org\/10.1007\/s11192-009-0146-3.","journal-title":"Scientometrics"},{"issue":"10","key":"4870_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223994","volume":"14","author":"C Chen","year":"2019","unstructured":"Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One. 2019;14(10):e0223994. https:\/\/doi.org\/10.1371\/journal.pone.0223994.","journal-title":"PLoS One"},{"issue":"1","key":"4870_CR40","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1073\/pnas.0307513100","volume":"101","author":"C Chen","year":"2004","unstructured":"Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101(1):5303\u201310. https:\/\/doi.org\/10.1073\/pnas.0307513100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4870_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/asi.22968","volume":"65","author":"C Chen","year":"2014","unstructured":"Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Assoc Inf Sci Technol. 2014;65(2):334\u201351. https:\/\/doi.org\/10.1002\/asi.22968.","journal-title":"J Assoc Inf Sci Technol"},{"issue":"4","key":"4870_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C. Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959\u201375. https:\/\/doi.org\/10.1016\/j.joi.2017.08.007.","journal-title":"J Informetr"},{"issue":"8","key":"4870_CR43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4870_CR44","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(19)30569-8.","journal-title":"Lancet Oncol"},{"issue":"20","key":"4870_CR45","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325-U39. https:\/\/doi.org\/10.1200\/JCO.2016.67.0448.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4870_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"issue":"1007","key":"4870_CR47","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1259\/bjr\/22373346","volume":"84","author":"M Teoh","year":"2011","unstructured":"Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967\u201396. https:\/\/doi.org\/10.1259\/bjr\/22373346.","journal-title":"Br J Radiol"},{"issue":"8","key":"4870_CR48","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(16)30070-5.","journal-title":"Lancet Oncol"},{"issue":"15","key":"4870_CR49","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N Van As","year":"2024","unstructured":"Van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391(15):1413\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2403365.","journal-title":"N Engl J Med"},{"issue":"5","key":"4870_CR50","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","volume":"68","author":"PA Kupelian","year":"2007","unstructured":"Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.01.067.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4870_CR51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","volume":"102","author":"RM Meier","year":"2018","unstructured":"Meier RM, Bloch DA, Cotrutz C, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018;102(2):296\u2013303. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"4870_CR52","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, Van Der Voet H, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4.","journal-title":"Lancet Oncol"},{"issue":"25","key":"4870_CR53","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","volume":"23","author":"H Lukka","year":"2005","unstructured":"Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.06.153.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4870_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","volume":"78","author":"G Arcangeli","year":"2010","unstructured":"Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase iii randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.07.1691.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4870_CR55","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","volume":"84","author":"S Arcangeli","year":"2012","unstructured":"Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.02.049.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4870_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ijrobp.2018.10.020","volume":"103","author":"CY Fung","year":"2019","unstructured":"Fung CY, Chen E, Vapiwala N, et al. The american society for radiation oncology 2017 radiation oncologist workforce study. Int J Radiat Oncol Biol Phys. 2019;103(3):547\u201356. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.10.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4870_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.radonc.2021.01.003","volume":"157","author":"D Rodin","year":"2021","unstructured":"Rodin D, Tawk B, Mohamad O, et al. Original hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey. Radiother Oncol. 2021;157:32\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.003.","journal-title":"Radiother Oncol"},{"issue":"3","key":"4870_CR58","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.radonc.2015.05.011","volume":"115","author":"NG Zaorsky","year":"2015","unstructured":"Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015;115(3):295\u2013300. https:\/\/doi.org\/10.1016\/j.radonc.2015.05.011.","journal-title":"Radiother Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04870-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:31:14Z","timestamp":1777937474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4870"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04870-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a bibliometric analysis based on metadata retrieved from the Web of Science Core Collection database. It does not utilize any human participants or animal experiments; therefore, ethical approval is not required. Not applicable. This research does not involve human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data, images, or case reports throughout the text.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"686"}}